For 23 years, I was an attorney in the Division of Investment Management at the U.S. Securities and Exchange Commission in Washington, D.C.
I expect many of my posts to focus on health and medicine. I became interested in medical research while researching treatment options for my then-teenage daughter, who has heterozygous familial hypercholesterolemia, a genetic disease that causes very high LDL-cholesterol. I am a member of the Walking Gallery of Healthcare. In addition, I am a member/administrator of the Familial Hypercholesterolemia (FH) Discussion Group on Facebook (https://www.facebook.com/#!/groups/47098836197/). In September 2013, I became a member of the editorial board of Circulation: Cardiovascular Quality and Outcomes, one of the American Heart Association journals. From November 2013 to September 2015, I was a member of the ABIM Assessment 2020 Task Force. I am also a patient reviewer for BMJ and an associate editor for the Society for Participatory Medicine newsletter.
Contact me at mannm at comcast.net. Follow me on Twitter @MarilynMann.
Comments without a valid email address will be deleted.
Disclosures: I received travel expenses from the American Board of Internal Medicine in 2015 to attend meetings of the Assessment 2020 Task Force. I received travel expenses from the American College of Cardiology in 2016 to attend the Cardiovascular Innovation Summit.
My husband and I do not own any securities of drug or device manufacturers. My mother, and a trust created at the time of my father’s death, hold securities of certain drug and device manufacturers, and I and my siblings are beneficiaries and will receive payouts at the time of my mother’s death. I am not involved in the management of my parents’ assets. Most likely the actual securities will not be distributed but rather will be sold so that cash can be distributed.